291 related articles for article (PubMed ID: 21565900)
1. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
Kristensen LE; Petersson IF; Geborek P; Jöud A; Saxne T; Jacobsson LT; Englund M
Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
[TBL] [Abstract][Full Text] [Related]
2. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
3. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Karlsson JA; Englund M; Petersson IF; Saxne T; Geborek P
Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
[TBL] [Abstract][Full Text] [Related]
4. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
5. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.
Neovius M; Simard JF; Klareskog L; Askling J;
Ann Rheum Dis; 2011 Aug; 70(8):1407-14. PubMed ID: 21518724
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
7. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis.
Keat AC; Gaffney K; Gilbert AK; Harris C; Leeder J
Rheumatology (Oxford); 2008 Apr; 47(4):481-3. PubMed ID: 18281690
[TBL] [Abstract][Full Text] [Related]
8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
9. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
Olofsson T; Englund M; Saxne T; Jöud A; Jacobsson LT; Geborek P; Allaire S; Petersson IF
Ann Rheum Dis; 2010 Dec; 69(12):2131-6. PubMed ID: 20693274
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for disability pension in a population-based cohort of men and women on long-term sick leave in Sweden.
Karlsson NE; Carstensen JM; Gjesdal S; Alexanderson KA
Eur J Public Health; 2008 Jun; 18(3):224-31. PubMed ID: 18245150
[TBL] [Abstract][Full Text] [Related]
12. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis.
Listing J; Brandt J; Rudwaleit M; Zink A; Sieper J; Braun J
Ann Rheum Dis; 2004 Dec; 63(12):1670-2. PubMed ID: 15547093
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
14. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.
Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2012 Nov; 64(11):3502-10. PubMed ID: 22886739
[TBL] [Abstract][Full Text] [Related]
15. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
16. Risk of sick leave and disability pension in working-age women and men with knee osteoarthritis.
Hubertsson J; Petersson IF; Thorstensson CA; Englund M
Ann Rheum Dis; 2013 Mar; 72(3):401-5. PubMed ID: 22679305
[TBL] [Abstract][Full Text] [Related]
17. Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.
Wallman JK; Jöud A; Olofsson T; Jacobsson LTH; Bliddal H; Kristensen LE
Rheumatology (Oxford); 2017 May; 56(5):716-724. PubMed ID: 28064208
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
19. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
[TBL] [Abstract][Full Text] [Related]
20. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
